May 4, 2018 8:30am-2:30pm
In partnership with Ernst & Young and Scientific American, Bioethics International is hosting a Forum on what it means to be a purpose driven, patient-centered and ethical pharma and health-innovation company.
Location: New York, NY
March 20, 2018
March 1, 2018
February 12, 2018
April 27, 2018 — May 4, 2018
BEI’s Inaugural
Bioethics Genius Prize
Apply by April 27, 2018
We are looking to support and recognize a bioethics innovator—a person or team who are not just thinking about how to improve ethics and patient centricity in healthcare innovation, but who are also making it happen. Are you working to raise the bar and operationalize bioethics in healthcare innovation? If so, apply by April 27th, for our inaugural Bioethics Genius Prize.
May 4, 2018 8:30am-2:30pm
In partnership with Ernst & Young and Scientific American, Bioethics International is hosting a Forum on what it means to be a purpose driven, patient-centered and ethical pharma and health-innovation company.
Location: New York, NY
The New York Times interviewed our founder, Jennifer Miller, on FDA Commissioner Dr. Scott Gottlieb's clinical trial transparency initiatives. She discussed his new pilot, launched last month, which selects 9 recently-approved drugs, whose sponsors (generally pharmaceutical companies) volunteer to participate, to post portions of Clinical Study Reports (CSRs) from their pivotal trials on FDA's website…
February 12, 2018
This week we focused on the ethics of Big Data, publishing an article titled, Big Data Probably Knows More About You Than Your Friends Do, in Leaps Mag. The article discusses the promises and perils of big data and concludes with a way to manage your data wealth. To read the full article click here.
February 7, 2018
Cross-sectional descriptive analysis of all clinical trials supporting 2014 Food and Drugs Administration (FDA)-approved new drug applications (NDAs) for novel drugs sponsored by large companies.
Disclosing clinical trial data is a step in the right direction towards transparency, which benefits both the public and the pharmaceutical industry.